N-Terminal domain antiandrogens are a novel type of
antiandrogen that bind to the
N-terminal domain of the
androgen receptor (AR) instead of the
ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated
gene transcription. They are being investigated for the treatment of
prostate cancer.
N-Terminal domain antiandrogens are a novel type of
antiandrogen that bind to the
N-terminal domain of the
androgen receptor (AR) instead of the
ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated
gene transcription. They are being investigated for the treatment of
prostate cancer.